dorzolamide hydrochloride

dorzolamide hydrochloride

[dorzo′lämīd]
a carbonic acid anhydrase inhibitor used in treatment of open-angle glaucoma and ocular hypertension, administered topically to the conjunctiva as the hydrochloride salt.
indications It is prescribed in the treatment of glaucoma. It reduces intraocular pressure by decreasing the rate of fluid production.
contraindications It should not be given to patients wearing soft contact lenses or those with allergy to dorzolamide or its components or related substances.
adverse effects The side effects most often reported include ocular burning, stinging or discomfort following use; tearing; blurred vision; or light sensitivity.
Mentioned in ?
References in periodicals archive ?
Effects of topical 2% dorzolamide hydrochloride alone and in combination with 0.
28 /PRNewswire/ -- Prasco announced today it has begun shipping generic forms of Dorzolamide Hydrochloride-Timolol Maleate and Dorzolamide Hydrochloride Ophthalmic Solutions, comparable to Merck's COSOPT(R) and TRUSOPT(R).
Dorzolamide hydrochloride-timolol maleate and dorzolamide hydrochloride ophthalmic solutions are indicated for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
MASON, Ohio -- Prasco announced today it has begun shipping generic forms of Dorzolamide Hydrochloride-Timolol Maleate and Dorzolamide Hydrochloride Ophthalmic Solutions, comparable to Merck's COSOPT([R]) and TRUSOPT([R]).
NASDAQ: HITK) announced today that the US Food and Drug Administration (FDA) has granted tentative approval to the Company's Abbreviated New Drug Application (ANDA) for dorzolamide hydrochloride with timolol maleate ophthalmic solution.
TRUSOPT Sterile Ophthalmic Solution is supplied as a sterile, isotonic, buffered, slightly viscous, aqueous solution of dorzolamide hydrochloride.
TRUSOPT Ophthalmic Solution contains dorzolamide hydrochloride, an inhibitor of human carbonic anhydrase II.
In a two-year study of dorzolamide hydrochloride administered orally to male and female Sprague-Dawley rats, urinary bladder papillomas were seen in male rats in the highest dosage group of 20 mg/kg/day (250 times the recommended human ophthalmic dose).
No changes in bladder urothelium were seen in dogs given oral dorzolamide hydrochloride for one year at 2 mg/kg/day (25 times the recommended human ophthalmic dose) or monkeys dosed topically to the eye at 0.
In reproduction studies of dorzolamide hydrochloride in rats, there were no adverse effects on the reproductive capacity of males or females at doses up to 188 or 94 times, respectively, the recommended human ophthalmic dose.
Developmental toxicity studies with dorzolamide hydrochloride in rabbits at oral doses of greater than or equal to 2.
Tenders are invited for Supply Of 1) Dorzolamide Hydrochloride Opthalmic Solution 2% W/V Bott Of 5 Ml.